NTRS - NASA Technical Reports Server

Back to Results
Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapyPatients with human immunodeficiency virus type 1 (HIV-1) infection are at high risk of developing Epstein-Barr virus (EBV)-associated lymphoma. However, little is known of the EBV DNA loads in patients receiving highly active antiretroviral therapy (HAART). Using a real-time quantitative polymerase chain reaction assay, we demonstrated that significantly more HIV-1-infected patients receiving HAART than HIV-1-uninfected volunteers had detectable EBV DNA in blood (57 [81%] of 70 vs. 11 [16%] of 68 patients; P=.001) and saliva (55 [79%] of 68 vs. 37 [54%] of 68 patients; P=.002). The mean EBV loads in blood and saliva samples were also higher in HIV-1-infected patients than in HIV-1-uninfected volunteers (P=.001). The frequency of EBV detection in blood was associated with lower CD4+ cell counts (P=.03) among HIV-1-infected individuals, although no differences were observed in the EBV DNA loads in blood or saliva samples in the HIV-1-infected group. Additional studies are needed to determine whether EBV-specific CD4+ and CD8+ cells play a role in the pathogenesis of EBV in HIV-1-infected patients receiving HAART.
Document ID
Document Type
Reprint (Version printed in journal)
External Source(s)
Ling, Paul D. (Baylor College of Medicine Houston, Texas 77030, United States)
Vilchez, Regis A.
Keitel, Wendy A.
Poston, David G.
Peng, Rong Sheng
White, Zoe S.
Visnegarwala, Fehmida
Lewis, Dorothy E.
Butel, Janet S.
Date Acquired
August 21, 2013
Publication Date
November 1, 2003
Publication Information
Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume: 37
Issue: 9
ISSN: 1058-4838
Subject Category
Life Sciences (General)
Funding Number(s)
Distribution Limits
NASA Discipline Regulatory Physiology
NASA Program Biomedical Research and Countermeasures
Non-NASA Center